Turning Point Therapeutics Inc

NASDAQ:TPTX   3:59:59 PM EDT
32.54
+0.73 (+2.30%)
4:05:28 PM EDT: $32.10 -0.44 (-1.35%)
Products

Turning Point Therapeutics Announces Pipeline Expansion, Licensing Of TPX-4589 (LM-302)

Published: 05/05/2022 13:20 GMT
Turning Point Therapeutics Inc (TPTX) - Turning Point Therapeutics Announces Pipeline Expansion, Licensing of Tpx-4589 (lm-302), a Clinical Stage Anti-claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines.
Turning Point Therapeutics Inc - Under Terms of Licensing Agreement, Lanova Will Receive an Upfront Payment of $25 Million.
Turning Point - Under Terms of Agreement, Lanova Eligible to Receive Up to an Additional $195 Million in Development & Regulatory Milestone Payments.
Turning Point- in Deal, Lanova Eligible to Receive Commercial Sales Milestones.
Turning Point- in Deal, Lanova Eligible to Receive Tiered Royalties Ranging From Mid-single Digit to Mid-teens Percentages on Net Sales.